{"success":true,"data":{"pressRelease":{"id":"27735","rtpr_id":"nGNX8F0q6V","ticker":"BIOA","exchange":"NASDAQ","all_tickers":["BIOA"],"title":"BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates","author":"Globe Newswire","published_at":"2026-05-08T13:00:00.757Z","article_body":"Positive topline Phase 1 data for BGE-102, demonstrating potential\nbest-in-class reductions among oral NLRP3 inhibitors in inflammatory\nbiomarkers of cardiovascular risk\n\nPhase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk\nplanned to initiate in mid-2026, with data anticipated by end of year\n\nPhase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema (DME)\nplanned to initiate in mid-2026, with data anticipated in mid-2027\n\nCompleted upsized follow-on public offering of $132.3 million\n\nEMERYVILLE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(NASDAQ: BIOA) (\"BioAge” or, \"the Company\"), a clinical-stage\nbiopharmaceutical company developing therapeutic product candidates for\ncardiometabolic diseases by targeting the biology of human aging, today\nprovided business updates and reported its first quarter 2026 financial\nresults.\n\n“The positive topline Phase 1 data we reported for BGE-102 in April\nreinforce our conviction that we have a potential best-in-class NLRP3\ninhibitor: a well-tolerated, once-daily oral therapy that could deliver the\nanti-inflammatory efficacy of injectables,\" said Kristen Fortney, Ph.D., CEO\nand co-founder of BioAge. \"Our focus now is execution. We plan to initiate two\nBGE-102 proof-of-concept trials by mid-2026 — a Phase 2 dose-ranging trial\nin cardiovascular risk, and a Phase 1b/2a trial in diabetic macular edema —\nadvancing BGE-102 as a potential 'pipeline in a pill' across cardiometabolic\nand ocular diseases. With the $132.3 million we raised in our upsized\nfollow-on offering earlier this year, we have the capital to drive both\nprograms through key milestones.”\n\nFirst Quarter 2026 Business Highlights\n\nNLRP3 inhibitor clinical development\n* In April 2026, BioAge reported positive topline data from the Phase 1 trial\nof BGE-102, its oral, brain-penetrant NLRP3 inhibitor, including a newly\nannounced 60 mg once-daily cohort in participants with obesity and elevated\ninflammation.\n* Across both 60 mg and 120 mg once-daily dose levels, BGE-102 achieved rapid\nand profound reductions in hsCRP, with median reductions of 86% from baseline,\ntogether with consistent reductions in IL-6 and fibrinogen.\n* At both doses, 87–93% of participants on active treatment reached\nnormalized hsCRP (<2 mg/L) — a threshold associated with reduced\ncardiovascular risk.\n* BGE-102 was well tolerated across all dose levels evaluated. All\ntreatment-emergent adverse events were mild to moderate in severity and\nself-limited, with no dose dependency. There were no serious adverse events,\nno treatment-emergent adverse events leading to discontinuation, and no\nclinically meaningful changes in vital signs, ECGs, or laboratory values.\n* Based on the full Phase 1 dataset, the Company plans to initiate a Phase 2\ndose-ranging proof-of-concept trial of BGE-102 in participants at elevated\ncardiovascular risk in mid-2026, with topline data anticipated by year end.\nBGE-102 indication expansion into ophthalmology\n* In January 2026, BioAge announced the expansion of its BGE-102 development\nprogram into ophthalmology, with an initial proof-of-concept study planned in\npatients with DME.\n* The Company plans to initiate a Phase 1b/2a proof-of-concept trial in\nmid-2026, with results anticipated in mid-2027.\nAPJ agonist program advancement\n* BioAge continues to advance its oral and injectable APJ agonist development\nstrategy, including a novel APJ agonist antibody that is the subject of an\noption agreement with JiKang Therapeutics. The Company intends to file its\nfirst IND for an APJ program by year-end 2026.\nUpsized follow-on public offering\n* In January 2026, BioAge completed an upsized follow-on public offering, with\nthe underwriters' option to purchase additional shares exercised in full in\nFebruary 2026, resulting in total gross proceeds of approximately $132.3\nmillion.\nStrategic partnerships and discovery platform\n* BioAge's multi-year research collaboration with Novartis, focused on\ndiscovering novel therapeutic targets at the intersection of aging biology and\nexercise physiology, continued to advance, with multiple targets under\nevaluation.\n* The Company also continued to progress its strategic collaboration with\nLilly ExploR&D for the development of therapeutic antibodies targeting novel\nmetabolic aging targets.\nFirst Quarter 2026 Financial Results\n\nCollaboration revenue was $2.8 million for the quarter ended March 31, 2026,\ncompared to $1.5 million for the same period in 2025. The $1.3 million\nincrease in collaboration revenue was due to increased full-time equivalent\nemployee (FTE) effort under the Novartis collaboration agreement, resulting in\nhigher revenue recognized based on progress toward satisfaction of the related\nperformance obligation.\n\nResearch and development expenses were approximately $20.4 million for the\nquarter ended March 31, 2026, compared to $11.1 million for the same period in\n2025. The $9.3 million increase in research and development expenses was\nprimarily attributable to a $5.7 million increase in direct costs related to\nthe BioAge’s BGE-102 program associated with the completion of the Phase 1\nsingle ascending dose (SAD) / multiple ascending dose (MAD) clinical trial,\npreparation for the planned Phase 2 dose-ranging proof-of-concept trial\nevaluating BGE-102 in participants with elevated cardiovascular risk and\nplanned Phase 1b/2a proof-of-concept trial in DME, each expected to initiate\nin mid-2026, and drug-product manufacturing. Additionally contributing to the\nincrease was a $3.6 million increase in direct costs for other programs, which\nwas primarily related to discovery and development activities related to\nBioAge’s novel apelin receptor APJ agonist programs, and a $0.8 million\nincrease in allocated facility and other expenses primarily driven by an\nincrease in non-program specific consulting fees. These increases were\npartially offset by a $0.8 million reduction in azelaprag direct costs\nfollowing termination of development in January 2025.\n\nGeneral and administrative expenses were $7.7 million for the quarter ended\nMarch 31, 2026, compared to $6.8 million for the same period in 2025. The $0.9\nmillion increase was primarily attributable to a $0.6 million increase in\npersonnel-related expenses, largely due to an increase in stock-based\ncompensation expense associated with new option grants issued to employees,\nexecutives, board members, and advisors, and a $0.4 million increase in legal\nfees, partially offset by a $0.1 million decrease in consulting expenses.\n\nNet loss was $22.3 million for the quarter ended March 31, 2026, or $0.52 per\nweighted-average common share outstanding, basic and diluted, compared to a\nnet loss of $12.9 million, or $0.36 per weighted-average common share\noutstanding, basic and diluted, for the same period in 2025.\n\nAs of March 31, 2026, BioAge had approximately $384.9 million in cash, cash\nequivalents, and marketable securities. Based on its current operating plan,\nBioAge estimates that existing cash and cash equivalents will be sufficient to\nfund operations and capital expenses through 2029.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company's lead product candidate, BGE-102, is a potent,\norally available, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for cardiovascular risk and retinal diseases including diabetic\nmacular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a\nwell-tolerated profile and potential best-in-class reductions in hsCRP and\nother inflammatory biomarkers in participants with obesity and elevated\ninflammation. Phase 2 cardiovascular risk proof-of-concept data are\nanticipated by end of year 2026, and Phase 1b/2a diabetic macular edema\nproof-of-concept data are anticipated in mid-2027. The Company is also\ndeveloping long-acting injectable and oral small molecule APJ agonists for\nobesity. BioAge’s additional preclinical programs, which leverage insights\nfrom the Company’s proprietary discovery platform built on human longevity\ndata, address key pathways involved in metabolic aging.\n\nForward-looking statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of, and made pursuant to the safe harbor provisions of, the Private\nSecurities Litigation Reform Act of 1995. In some cases, you can identify\nforward-looking statements by terms such as “aim,” “may,” “will,”\n“should,” “expect,” “forecast,” “plan,” “anticipate,”\n“could,” “intend,” “target,” “project,” “contemplate,”\n“believe,” “estimate,” “predict,” “potential” or\n“continue” or the negative of these terms or other similar expressions,\nalthough not all forward-looking statements contain these words. All\nstatements other than statements of historical fact contained in this press\nrelease, including without limitation statements regarding our plans to\ndevelop and commercialize our product candidates, including BGE-102 and our\nAPJ programs, the potential for BGE-102 as a treatment for atherosclerotic\ncardiovascular disease risk reduction and diabetic macular edema, the expected\ntimeline for data readouts from our ongoing Phase 1 clinical trial, the\nexpected timing and results of our ongoing or planned preclinical studies and\nclinical trials, risks associated with clinical trials, including our ability\nto adequately manage clinical activities for BGE-102 and our APJ programs,\nunexpected concerns that may arise from additional data or analysis obtained\nduring clinical trials, the timing of and our ability to obtain and maintain\nregulatory approvals, the clinical utility of our future product candidates,\nour commercialization, marketing and manufacturing capabilities and strategy,\nour expectations about the willingness of healthcare professionals to use our\nproduct candidates, the sufficiency of our cash, cash equivalents and\nmarketable securities, general economic conditions, the impact of industry and\nmarket conditions on our operations, including fluctuating interest rates and\ninflation, increased volatility in the debt and equity markets, legislative or\nregulatory healthcare reforms in the United States, significant political,\ntrade or regulatory developments, including tariffs, federal government\nshutdowns, or shifting priorities within the U.S. Food and Drug\nAdministration, cybersecurity incidents, and global regional conflicts, and\nthe plans and objectives of management for future operations and capital\nexpenditures are forward-looking statements.\n\nThe forward-looking statements in this press release are only predictions and\nare based largely on our current expectations and projections about future\nevents and financial trends that we believe may affect our business, financial\ncondition and results of operations. These forward-looking statements speak\nonly as of the date of this press release and are subject to a number of known\nand unknown risks, uncertainties and assumptions, including those described\nunder the headings “Risk Factors” and “Management’s Discussion and\nAnalysis of Financial Condition and Results of Operations” included in\nBioAge’s Quarterly Report on Form 10-Q filed with the U.S. Securities and\nExchange Commission (SEC) on May 8, 2026, and BioAge’s other filings with\nthe SEC filed from time to time.\n\nBecause forward-looking statements are inherently subject to risks and\nuncertainties, some of which cannot be predicted or quantified and some of\nwhich are beyond our control, you should not rely on these forward-looking\nstatements as predictions of future events. The events and circumstances\nreflected in our forward-looking statements may not be achieved or occur and\nactual results could differ materially from those projected in the\nforward-looking statements. Moreover, we operate in an evolving environment.\nNew risk factors and uncertainties may emerge from time to time, and it is not\npossible for management to predict all risk factors and uncertainties. BioAge\nundertakes no obligation to publicly update any forward-looking statement,\nwhether written or oral, that may be made from time to time, whether as a\nresult of new information, future developments or otherwise.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com \n\n BIOAGE LABS, INC. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share information) \n \n Three Months Ended \n March 31, \n 2026 2025 \n Collaboration revenue $ 2,772 $ 1,451 \n Operating expenses: \n Research and development $ 20,410 $ 11,109 \n General and administrative 7,737 6,788 \n Total operating expenses 28,147 17,897 \n Loss from operations (25,375 ) (16,446 ) \n Other income (expense) \n Interest expense (39 ) (255 ) \n Interest and other income (expense), net 3,268 3,714 \n Gain (loss) from changes in fair value of warrants (107 ) 59 \n Total other income (expense), net 3,122 3,518 \n Net loss $ (22,253 ) $ (12,928 ) \n Net loss per share attributable to common stockholders, basic and diluted $ (0.52 ) $ (0.36 ) \n Weighted-average common shares outstanding, basic and diluted 42,480,488 35,850,037 \n Comprehensive loss: \n Net loss (22,253 ) (12,928 ) \n Other comprehensive income (loss): \n Unrealized holding gains (losses) on available-for-sale investments (178 ) 29 \n Foreign currency translation adjustment (27 ) (10 ) \n Total other comprehensive income (loss): (205 ) 19 \n Total comprehensive loss $ (22,458 ) $ (12,909 ) \n \n\n\n\n BIOAGE LABS, INC. \n Unaudited Condensed Consolidated Balance Sheets \n (in thousands, except share and per share information) \n \n March 31, December 31, \n 2026 2025 \n Assets \n Current Assets: \n Cash and cash equivalents $ 241,777 $ 188,888 \n Marketable securities, current 141,417 92,210 \n Accounts receivable 709 769 \n Prepaid expenses and other current assets 7,957 4,926 \n Total current assets 391,860 286,793 \n Investments 100 100 \n Marketable securities 1,680 4,032 \n Property and equipment, net 1,115 963 \n Operating lease right-of-use assets 2,684 2,785 \n Other assets 215 216 \n Total assets $ 397,654 $ 294,889 \n Liabilities \n Current Liabilities: \n Accounts payable $ 3,066 $ 2,674 \n Accrued expenses and other current liabilities 4,765 8,480 \n Current portion of term loan 1,159 2,648 \n Operating lease liabilities, current 646 582 \n Deferred revenue 6,191 5,754 \n Total current liabilities 15,827 20,138 \n Warrant liability 477 370 \n Operating lease liabilities 2,229 2,330 \n Total liabilities 18,533 22,838 \n Commitments and Contingencies (Note 7) \n Stockholders’ Equity \n Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding as of March 31, 2026 and December 31, 2025 — — \n Common stock, $0.00001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 44,386,785 and 37,386,908 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively — — \n Additional paid-in-capital 734,717 605,189 \n Accumulated other comprehensive income 73 278 \n Accumulated deficit (355,669 ) (333,416 ) \n Total stockholders’ equity 379,121 272,051 \n Total liabilities and stockholders’ equity $ 397,654 $ 294,889 \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8F0q6V","title":"BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates","author":"Globe Newswire","ticker":"BIOA","created":"2026-05-08T13:00:00.757Z","tickers":["BIOA"],"exchange":"NASDAQ","article_body":"Positive topline Phase 1 data for BGE-102, demonstrating potential\nbest-in-class reductions among oral NLRP3 inhibitors in inflammatory\nbiomarkers of cardiovascular risk\n\nPhase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk\nplanned to initiate in mid-2026, with data anticipated by end of year\n\nPhase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema (DME)\nplanned to initiate in mid-2026, with data anticipated in mid-2027\n\nCompleted upsized follow-on public offering of $132.3 million\n\nEMERYVILLE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(NASDAQ: BIOA) (\"BioAge” or, \"the Company\"), a clinical-stage\nbiopharmaceutical company developing therapeutic product candidates for\ncardiometabolic diseases by targeting the biology of human aging, today\nprovided business updates and reported its first quarter 2026 financial\nresults.\n\n“The positive topline Phase 1 data we reported for BGE-102 in April\nreinforce our conviction that we have a potential best-in-class NLRP3\ninhibitor: a well-tolerated, once-daily oral therapy that could deliver the\nanti-inflammatory efficacy of injectables,\" said Kristen Fortney, Ph.D., CEO\nand co-founder of BioAge. \"Our focus now is execution. We plan to initiate two\nBGE-102 proof-of-concept trials by mid-2026 — a Phase 2 dose-ranging trial\nin cardiovascular risk, and a Phase 1b/2a trial in diabetic macular edema —\nadvancing BGE-102 as a potential 'pipeline in a pill' across cardiometabolic\nand ocular diseases. With the $132.3 million we raised in our upsized\nfollow-on offering earlier this year, we have the capital to drive both\nprograms through key milestones.”\n\nFirst Quarter 2026 Business Highlights\n\nNLRP3 inhibitor clinical development\n* In April 2026, BioAge reported positive topline data from the Phase 1 trial\nof BGE-102, its oral, brain-penetrant NLRP3 inhibitor, including a newly\nannounced 60 mg once-daily cohort in participants with obesity and elevated\ninflammation.\n* Across both 60 mg and 120 mg once-daily dose levels, BGE-102 achieved rapid\nand profound reductions in hsCRP, with median reductions of 86% from baseline,\ntogether with consistent reductions in IL-6 and fibrinogen.\n* At both doses, 87–93% of participants on active treatment reached\nnormalized hsCRP (<2 mg/L) — a threshold associated with reduced\ncardiovascular risk.\n* BGE-102 was well tolerated across all dose levels evaluated. All\ntreatment-emergent adverse events were mild to moderate in severity and\nself-limited, with no dose dependency. There were no serious adverse events,\nno treatment-emergent adverse events leading to discontinuation, and no\nclinically meaningful changes in vital signs, ECGs, or laboratory values.\n* Based on the full Phase 1 dataset, the Company plans to initiate a Phase 2\ndose-ranging proof-of-concept trial of BGE-102 in participants at elevated\ncardiovascular risk in mid-2026, with topline data anticipated by year end.\nBGE-102 indication expansion into ophthalmology\n* In January 2026, BioAge announced the expansion of its BGE-102 development\nprogram into ophthalmology, with an initial proof-of-concept study planned in\npatients with DME.\n* The Company plans to initiate a Phase 1b/2a proof-of-concept trial in\nmid-2026, with results anticipated in mid-2027.\nAPJ agonist program advancement\n* BioAge continues to advance its oral and injectable APJ agonist development\nstrategy, including a novel APJ agonist antibody that is the subject of an\noption agreement with JiKang Therapeutics. The Company intends to file its\nfirst IND for an APJ program by year-end 2026.\nUpsized follow-on public offering\n* In January 2026, BioAge completed an upsized follow-on public offering, with\nthe underwriters' option to purchase additional shares exercised in full in\nFebruary 2026, resulting in total gross proceeds of approximately $132.3\nmillion.\nStrategic partnerships and discovery platform\n* BioAge's multi-year research collaboration with Novartis, focused on\ndiscovering novel therapeutic targets at the intersection of aging biology and\nexercise physiology, continued to advance, with multiple targets under\nevaluation.\n* The Company also continued to progress its strategic collaboration with\nLilly ExploR&D for the development of therapeutic antibodies targeting novel\nmetabolic aging targets.\nFirst Quarter 2026 Financial Results\n\nCollaboration revenue was $2.8 million for the quarter ended March 31, 2026,\ncompared to $1.5 million for the same period in 2025. The $1.3 million\nincrease in collaboration revenue was due to increased full-time equivalent\nemployee (FTE) effort under the Novartis collaboration agreement, resulting in\nhigher revenue recognized based on progress toward satisfaction of the related\nperformance obligation.\n\nResearch and development expenses were approximately $20.4 million for the\nquarter ended March 31, 2026, compared to $11.1 million for the same period in\n2025. The $9.3 million increase in research and development expenses was\nprimarily attributable to a $5.7 million increase in direct costs related to\nthe BioAge’s BGE-102 program associated with the completion of the Phase 1\nsingle ascending dose (SAD) / multiple ascending dose (MAD) clinical trial,\npreparation for the planned Phase 2 dose-ranging proof-of-concept trial\nevaluating BGE-102 in participants with elevated cardiovascular risk and\nplanned Phase 1b/2a proof-of-concept trial in DME, each expected to initiate\nin mid-2026, and drug-product manufacturing. Additionally contributing to the\nincrease was a $3.6 million increase in direct costs for other programs, which\nwas primarily related to discovery and development activities related to\nBioAge’s novel apelin receptor APJ agonist programs, and a $0.8 million\nincrease in allocated facility and other expenses primarily driven by an\nincrease in non-program specific consulting fees. These increases were\npartially offset by a $0.8 million reduction in azelaprag direct costs\nfollowing termination of development in January 2025.\n\nGeneral and administrative expenses were $7.7 million for the quarter ended\nMarch 31, 2026, compared to $6.8 million for the same period in 2025. The $0.9\nmillion increase was primarily attributable to a $0.6 million increase in\npersonnel-related expenses, largely due to an increase in stock-based\ncompensation expense associated with new option grants issued to employees,\nexecutives, board members, and advisors, and a $0.4 million increase in legal\nfees, partially offset by a $0.1 million decrease in consulting expenses.\n\nNet loss was $22.3 million for the quarter ended March 31, 2026, or $0.52 per\nweighted-average common share outstanding, basic and diluted, compared to a\nnet loss of $12.9 million, or $0.36 per weighted-average common share\noutstanding, basic and diluted, for the same period in 2025.\n\nAs of March 31, 2026, BioAge had approximately $384.9 million in cash, cash\nequivalents, and marketable securities. Based on its current operating plan,\nBioAge estimates that existing cash and cash equivalents will be sufficient to\nfund operations and capital expenses through 2029.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company's lead product candidate, BGE-102, is a potent,\norally available, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for cardiovascular risk and retinal diseases including diabetic\nmacular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a\nwell-tolerated profile and potential best-in-class reductions in hsCRP and\nother inflammatory biomarkers in participants with obesity and elevated\ninflammation. Phase 2 cardiovascular risk proof-of-concept data are\nanticipated by end of year 2026, and Phase 1b/2a diabetic macular edema\nproof-of-concept data are anticipated in mid-2027. The Company is also\ndeveloping long-acting injectable and oral small molecule APJ agonists for\nobesity. BioAge’s additional preclinical programs, which leverage insights\nfrom the Company’s proprietary discovery platform built on human longevity\ndata, address key pathways involved in metabolic aging.\n\nForward-looking statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of, and made pursuant to the safe harbor provisions of, the Private\nSecurities Litigation Reform Act of 1995. In some cases, you can identify\nforward-looking statements by terms such as “aim,” “may,” “will,”\n“should,” “expect,” “forecast,” “plan,” “anticipate,”\n“could,” “intend,” “target,” “project,” “contemplate,”\n“believe,” “estimate,” “predict,” “potential” or\n“continue” or the negative of these terms or other similar expressions,\nalthough not all forward-looking statements contain these words. All\nstatements other than statements of historical fact contained in this press\nrelease, including without limitation statements regarding our plans to\ndevelop and commercialize our product candidates, including BGE-102 and our\nAPJ programs, the potential for BGE-102 as a treatment for atherosclerotic\ncardiovascular disease risk reduction and diabetic macular edema, the expected\ntimeline for data readouts from our ongoing Phase 1 clinical trial, the\nexpected timing and results of our ongoing or planned preclinical studies and\nclinical trials, risks associated with clinical trials, including our ability\nto adequately manage clinical activities for BGE-102 and our APJ programs,\nunexpected concerns that may arise from additional data or analysis obtained\nduring clinical trials, the timing of and our ability to obtain and maintain\nregulatory approvals, the clinical utility of our future product candidates,\nour commercialization, marketing and manufacturing capabilities and strategy,\nour expectations about the willingness of healthcare professionals to use our\nproduct candidates, the sufficiency of our cash, cash equivalents and\nmarketable securities, general economic conditions, the impact of industry and\nmarket conditions on our operations, including fluctuating interest rates and\ninflation, increased volatility in the debt and equity markets, legislative or\nregulatory healthcare reforms in the United States, significant political,\ntrade or regulatory developments, including tariffs, federal government\nshutdowns, or shifting priorities within the U.S. Food and Drug\nAdministration, cybersecurity incidents, and global regional conflicts, and\nthe plans and objectives of management for future operations and capital\nexpenditures are forward-looking statements.\n\nThe forward-looking statements in this press release are only predictions and\nare based largely on our current expectations and projections about future\nevents and financial trends that we believe may affect our business, financial\ncondition and results of operations. These forward-looking statements speak\nonly as of the date of this press release and are subject to a number of known\nand unknown risks, uncertainties and assumptions, including those described\nunder the headings “Risk Factors” and “Management’s Discussion and\nAnalysis of Financial Condition and Results of Operations” included in\nBioAge’s Quarterly Report on Form 10-Q filed with the U.S. Securities and\nExchange Commission (SEC) on May 8, 2026, and BioAge’s other filings with\nthe SEC filed from time to time.\n\nBecause forward-looking statements are inherently subject to risks and\nuncertainties, some of which cannot be predicted or quantified and some of\nwhich are beyond our control, you should not rely on these forward-looking\nstatements as predictions of future events. The events and circumstances\nreflected in our forward-looking statements may not be achieved or occur and\nactual results could differ materially from those projected in the\nforward-looking statements. Moreover, we operate in an evolving environment.\nNew risk factors and uncertainties may emerge from time to time, and it is not\npossible for management to predict all risk factors and uncertainties. BioAge\nundertakes no obligation to publicly update any forward-looking statement,\nwhether written or oral, that may be made from time to time, whether as a\nresult of new information, future developments or otherwise.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com \n\n BIOAGE LABS, INC. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share information) \n \n Three Months Ended \n March 31, \n 2026 2025 \n Collaboration revenue $ 2,772 $ 1,451 \n Operating expenses: \n Research and development $ 20,410 $ 11,109 \n General and administrative 7,737 6,788 \n Total operating expenses 28,147 17,897 \n Loss from operations (25,375 ) (16,446 ) \n Other income (expense) \n Interest expense (39 ) (255 ) \n Interest and other income (expense), net 3,268 3,714 \n Gain (loss) from changes in fair value of warrants (107 ) 59 \n Total other income (expense), net 3,122 3,518 \n Net loss $ (22,253 ) $ (12,928 ) \n Net loss per share attributable to common stockholders, basic and diluted $ (0.52 ) $ (0.36 ) \n Weighted-average common shares outstanding, basic and diluted 42,480,488 35,850,037 \n Comprehensive loss: \n Net loss (22,253 ) (12,928 ) \n Other comprehensive income (loss): \n Unrealized holding gains (losses) on available-for-sale investments (178 ) 29 \n Foreign currency translation adjustment (27 ) (10 ) \n Total other comprehensive income (loss): (205 ) 19 \n Total comprehensive loss $ (22,458 ) $ (12,909 ) \n \n\n\n\n BIOAGE LABS, INC. \n Unaudited Condensed Consolidated Balance Sheets \n (in thousands, except share and per share information) \n \n March 31, December 31, \n 2026 2025 \n Assets \n Current Assets: \n Cash and cash equivalents $ 241,777 $ 188,888 \n Marketable securities, current 141,417 92,210 \n Accounts receivable 709 769 \n Prepaid expenses and other current assets 7,957 4,926 \n Total current assets 391,860 286,793 \n Investments 100 100 \n Marketable securities 1,680 4,032 \n Property and equipment, net 1,115 963 \n Operating lease right-of-use assets 2,684 2,785 \n Other assets 215 216 \n Total assets $ 397,654 $ 294,889 \n Liabilities \n Current Liabilities: \n Accounts payable $ 3,066 $ 2,674 \n Accrued expenses and other current liabilities 4,765 8,480 \n Current portion of term loan 1,159 2,648 \n Operating lease liabilities, current 646 582 \n Deferred revenue 6,191 5,754 \n Total current liabilities 15,827 20,138 \n Warrant liability 477 370 \n Operating lease liabilities 2,229 2,330 \n Total liabilities 18,533 22,838 \n Commitments and Contingencies (Note 7) \n Stockholders’ Equity \n Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding as of March 31, 2026 and December 31, 2025 — — \n Common stock, $0.00001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 44,386,785 and 37,386,908 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively — — \n Additional paid-in-capital 734,717 605,189 \n Accumulated other comprehensive income 73 278 \n Accumulated deficit (355,669 ) (333,416 ) \n Total stockholders’ equity 379,121 272,051 \n Total liabilities and stockholders’ equity $ 397,654 $ 294,889 \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-08T13:00:00.89180841Z","server_sent_at_ms":1778245200891},"received_at":"2026-05-08T13:00:00.999Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}